

# EmeritusDX Announces Launch of FDA Approved Therascreen BRAF and KRAS Tests, Expanding Molecular Testing Capabilities

NEWS PROVIDED BY

**EmeritusDX**

Apr 08, 2024, 06:00 ET



Headquarters in Lake Forest, CA

The Launch Aligns with the Company's Commitment to Personalized Care and Expanding its Companion Diagnostics Portfolio



LAKE FOREST, Calif., April 8, 2024 /PRNewswire-PRWeb/ -- EmeritusDX, a leading cancer diagnostics and information company, is excited to announce the launch of the FDA-approved theascreen® BRAF and KRAS tests. These innovative products represent a significant advancement in the company's molecular testing menu and aligns perfectly with its strategy of enhancing patient care.

"Our commitment at EmeritusDX has always been to deliver cutting-edge solutions that positively impact patient outcomes," said CEO Robert Embree. "The introduction of the theascreen® BRAF and KRAS portfolio is a testament to this commitment. It not only expands our molecular testing menu but also builds upon our patient care strategy. We are proud to offer these advanced diagnostic tools to our healthcare partners and their patients."

---

**"Our commitment at EmeritusDX has always been to deliver cutting-edge solutions that positively impact patient outcomes." CEO Robert Embree.**

✕ Post this

---

The theascreen® BRAF test is a companion diagnostic for encorafenib (Braftovi), a BRAF inhibitor used in treating adult patients with metastatic colorectal cancer (CRC) harboring a BRAF V600E mutation. This test is critical in identifying patients who are candidates for this targeted therapy.

The theascreen® KRAS test plays a crucial role in the identification of colorectal cancer (CRC) patients eligible for targeted therapies. It aids in the identification of CRC patients eligible for treatment with Erbitux® (cetuximab) or Vectibix® (panitumumab).

According to EmeritusDX's Chief Scientist, Dr. Vincent Funari, "The theascreen® BRAF and KRAS tests are a game-changer in personalized medicine for CRC patients. This precise approach ensures that patients receive the most effective treatment tailored to their specific genetic profile. EmeritusDX aims to address the dilemma of minimal biopsy material by increasing the likelihood of results with scant tumor samples while providing market leading turnaround times for patients and physicians."

EmeritusDX's latest offering underscores its dedication to advancing personalized medicine and reinforces its position as a pioneer in molecular diagnostics. The thetascreen® BRAF and KRAS tests are now available to healthcare providers, marking a new chapter in the company's journey towards revolutionizing patient care through innovative diagnostic solutions.

## About EmeritusDX

EmeritusDX is a cancer diagnostic and information company. Our expertise is in delivering actionable clinical information. Within our world-class laboratory, we perform testing that guides the diagnosis and treatment of cancer patients. Our partners include hospital and private pathology laboratories, biotechnology companies, academic institutions, contract research and pharmaceutical development organizations, and more. We understand the dependency on our accurate and timely results and our commitment to excellence in this regard is unwavering.

If you would like more information about this topic, please call 800-959-2846 or email [\*\*contact@emeritusdx.com\*\*](mailto:contact@emeritusdx.com)

Contact: Charles Caymus | EmeritusDX 12 Spectrum Pointe Drive | Lake Forest, CA  
[\*\*contact@emeritusdx.com\*\*](mailto:contact@emeritusdx.com) 800.959.2846

Note: Therascreen® is a registered trademark of Qiagen. Erbitux® is a registered trademark of Eli Lilly and Company. Vectibix® is a registered trademark of Amgen Inc. Braftovi® is a registered trademark of Pfizer Inc.

SOURCE EmeritusDX